United Therapeutics (UTHR) Capital Expenditures (2009 - 2026)

United Therapeutics has disclosed Capital Expenditures across 18 years of filings, most recently posting $108.0 million for Q2 2026.

• In Q2 2026, Capital Expenditures rose 73.63% year-over-year to $108.0 million; the TTM figure through Jun 2026 stood at $592.2 million (up 97.2% YoY), while the FY2025 annual figure was $520.5 million, up 111.16% from the prior year.
• Capital Expenditures came in at $108.0 million for Q2 2026 at United Therapeutics, up from $100.8 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $210.5 million in Q3 2025 to a low of $13.5 million in Q1 2022.
• Average Capital Expenditures over 5 years is $74.7 million, with a median of $67.2 million recorded in 2022.
• Year-over-year, Capital Expenditures tumbled 44.05% in 2022 and jumped 205.93% in 2023.
• Over 5 years, Capital Expenditures stood at $39.5 million in 2022, then surged by 99.24% to $78.7 million in 2023, then rose by 10.17% to $86.7 million in 2024, then jumped by 99.42% to $172.9 million in 2025, then sank by 37.54% to $108.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $108.0 million in Q2 2026, $100.8 million in Q1 2026, and $172.9 million in Q4 2025.